96Curated trials
Enterprise Evidence Report · NR-REPORT-V2.0
Hungary
Neuroscience Intelligence
Hungary neuroscience evidence report: current clinical, research, institution and source-linked intelligence.
Evidence rank #29 of 50 · Data maturity A · Research score 34.4 · Data confidence 100.0 / 100 · Snapshot 2026-10-12 03:34 UTC.
20Recruiting trials
28Publications
31Institutions
Executive interpretation
Hungary ranks #29 in the current NeuroRisk evidence-ranked market layer. This ranking summarizes indexed clinical, publication and institution evidence; it is not a probability of commercial success and not an investment recommendation.
Methodology status
Methodology NR-REPORT-V2.0. No synthetic ML confidence is presented as scientific probability. Counts and source links below are tied to the generation snapshot.
Methodology →Leading sponsors
Merck Sharp & Dohme LLC129 recruiting
Hoffmann-La Roche72 recruiting
Boehringer Ingelheim40 recruiting
Eisai Limited30 recruiting
UCB Pharma30 recruiting
GlaxoSmithKline30 recruiting
Novo Nordisk A/S30 recruiting
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.30 recruiting
Forest Laboratories20 recruiting
H. Lundbeck A/S20 recruiting
Disease activity
Parkinsons24trials
Epilepsy16trials
Alzheimers9trials
Multiple Sclerosis7trials
Autism5trials
Schizophrenia5trials
Depression4trials
Stroke3trials
Traumatic Brain Injury1trials
Bipolar Disorder1trials
Research institutions
Jahn Ferenc Dél-Pesti Kórház és RendelőintézetOpenAlexlinked institution
Institute of Materials and Environmental ChemistryOpenAlexlinked institution
University of SzegedOpenAlexlinked institution
Orszagos Kornyezetegeszsegugyi IntezetOpenAlexlinked institution
Heim Pál Országos Gyermekgyógyászati IntézetOpenAlexlinked institution
National Institute of Menthal Health, Neurology and Neurosurgery - Nyírő Gyula HospitalOpenAlexlinked institution
ImmunoGenes (Hungary)OpenAlexlinked institution
Szent János KórházOpenAlexlinked institution
Budapest University of Technology and EconomicsOpenAlexlinked institution
Pázmány Péter Catholic UniversityOpenAlexlinked institution
Clinical evidence trail
NCT07216703A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)RECRUITING
NCT06966700A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)RECRUITING
NCT06952504A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)RECRUITING
NCT06887192A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease PsychosisRECRUITING
NCT06798896RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset SeizuresRECRUITING
NCT06788912Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)RECRUITING
NCT06780085A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)RECRUITING
NCT06510816A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)ACTIVE_NOT_RECRUITING
NCT06180278Long-term, Open-label, Safety Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD)ACTIVE_NOT_RECRUITING
NCT05980949Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)RECRUITING
NCT05457283A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and ProteinuriaRECRUITING
Research evidence trail
PUBMEDThe salient role of childhood neglect in single and multiple suicide attempts among adult psychiatric inpatients.2026-12-01
PUBMEDSubjective experiences of catatonia in acute psychiatric inpatients: An exploratory study.2026-11-01
PUBMEDEarly-Life Feeding Behavior and Sensory Processing in Autism Spectrum Disorder: A Systematic Review and Meta-Analysis.2026-10-03
PUBMEDThe diagnostic order of migraine-depression comorbidity associates with physical, mental, and social disability.2026-10-01
PUBMEDEEG spectral power across rest, body scan, and task conditions in Autism and Schizophrenia.2026-10-01
PUBMEDPre-Treatment Levels of Inflammatory Biomarkers as Predictors of Reperfusion Outcomes in Acute Ischemic Stroke: A Systematic Review and Meta-analysis.2026-10-01
PUBMEDFeasibility and Pilot Validation of the ADHD Child Evaluation (ACEv.2) Clinical Interview.2026-09-06
PUBMEDEstablishment of a novel human nervous system tissue bank: University of Debrecen tissue bank-introduction and retrospective data analysis.2026-09-02
PUBMEDRe-Evaluating the Role of Statistical Learning: Domain-General Predictors of Language in Typical and Atypical Development.2026-09-01
PUBMEDObsessive-compulsive tendencies shift the balance between competitive neurocognitive functions.2026-08-21
PUBMEDPharmacological Modulation of the Kynurenine Pathway Using PF-04859989 Modulates PACAP Signaling in Migraine-Relevant Trigeminal Sensitization.2026-08-03
PUBMEDSemantic Content of Visual Consequent Stimuli Modulates Audiovisual Learning in Migraine.2026-08-01
Sources and provenance
ClinicalTrials.gov provides NCT evidence. PubMed/NCBI and OpenAlex provide research metadata. OpenAlex links institutions. World Bank indicators are included only when an explicit source row and year exist. NeuroRisk transformations add normalization, ranking and graph connections.
Limitations
Indexed corpus counts are not guaranteed exhaustive global totals. Scores are comparative decision-support signals. This report is not medical advice, regulatory advice, patent clearance, an investment recommendation or a guarantee of outcome.